Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cemiplimab or Cemiplimab Plus Fianlimab in Cutaneous Basal Cell Carcinoma of the Head and Neck
NCT05929664Phase 2Suspended
- Sponsor
- Thomas Jefferson University
- Start
- Jul 2023
- Primary completion
- Jul 2031
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, fianlimab in basal cell carcinoma (BCC), sponsored by Thomas Jefferson University. Started Jul 2023; status: suspended.
02
Drugs
cemiplimabfianlimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT05929664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929664.